Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 9186 · Controlled Substances Act Clarification in Sciences Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 802 Definitions

+42 −0Shown
More for 21 U.S.C. § 802
Read § 802Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by adding at the end the following:(61) The term “accepted medical use” means the use of a drug or other substance— (A) in accordance with an approval under the Federal Food, Drug, and Cosmetic Act or licensure under section 351 of the Public Health Service Act; (B) to conduct scientific research to advance the …

§ 802(59)–(69)

Start of § 802 to (59)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(59)(B)(B) (B)
any offense that would be a felony violation of section 113 of title 18, if the offense were committed in the special maritime and territorial jurisdiction of the United States, for which the offender served a term of imprisonment of more than 12 months.any offense that would be a felony violation of section 113 of title 18, if the offense were committed in the special maritime and territorial jurisdiction of the United States, for which the offender served a term of imprisonment of more than 12 months.
(60)(60) (60)
The term “fentanyl-related substance” has the meaning given the term in subsection (e)(2) of schedule I of section 812(c) of this title.The term “fentanyl-related substance” has the meaning given the term in subsection (e)(2) of schedule I of section 812(c) of this title.
(61)(61) [inserted: ]
[inserted: The term “accepted medical use” means the use of a drug or other substance—]
(61)(A)(A) [inserted: ]
[inserted: in accordance with an approval under the Federal Food, Drug, and Cosmetic Act or licensure under section 351 of the Public Health Service Act;]
(61)(B)(B) [inserted: ]
[inserted: to conduct scientific research to advance the understanding of human biology, develop new therapies, or research animal or human models of disease, syndrome, or disorder; or]
(61)(C)(C) [inserted: ]
[inserted: in accordance with a recognized legitimate medical use if—]
(61)(C)(i)(i) [inserted: ]
[inserted: a jurisdiction has authorized the drug or substance for medical use;]
(61)(C)(ii)(ii) [inserted: ]
[inserted: the drug or substance is widely used in such jurisdiction by health care practitioners; and]
(61)(C)(iii)(iii) [inserted: ]
[inserted: such legitimate medical use is recognized by the entities that regulate the practice of medicine in such jurisdiction through evidence-based scientific evaluation that employs rigorous and generally accepted methodologies.]
(62)(62) [inserted: ]
[inserted: The term “dependence liability” means, with respect to a drug or other substance that could contribute to a substance use disorder, the actual propensity for physical dependence or psychological dependence to the drug or substance.]
(63)(63) [inserted: ]
[inserted: The term “physical dependence” means, with respect to a drug or other substance, a state that develops as a result of physiological adaptation in response to repeated, chronic use of the drug or substance, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of the drug or substance.]
(64)(64) [inserted: ]
[inserted: The term “psychological dependence” means, with respect to a drug or other substance, a state in which an individual’s use of the drug or substance is compromised by—]
(64)(A)(A) [inserted: ]
[inserted: the rewarding effects of the drug or substance, thus increasing the likelihood of chronic use; or]
(64)(B)(B) [inserted: ]
[inserted: psychological distress (including craving) that occurs in the absence of the drug or substance and contributes to compulsive drug seeking, regardless of whether such use is indicative of abuse or misuse of the drug or substance.]
(65)(65) [inserted: ]
[inserted: The term “lack of accepted safety for use of the drug or other substance under medical supervision” means, with respect to a drug or other substance, that based on the accepted medical use of the drug or substance, a reasonable health care practitioner would determine that the potential risk of death or significant and irreversible harm to the user would clearly outweigh any medical benefit to the user.]
(66)(66) [inserted: ]
[inserted: The term “abuse” means, with respect to a drug or other substance, the intentional use of the drug or substance in a manner that will lead to a substance use disorder.]
(67)(67) [inserted: ]
[inserted: The term “potential for abuse” means, with respect to a drug or other substance, the relative likelihood that use of the drug or substance will result in abuse of the drug or substance.]
(68)(68) [inserted: ]
[inserted: The term “misuse” means—]
(68)(A)(A) [inserted: ]
[inserted: the use by an individual of a drug or other substance that is not intended for human consumption (determined in the same manner as such a determination would be made under section 203); or]
(68)(B)(B) [inserted: ]
[inserted: the use by an individual of a drug or other substance in a way—]
(68)(B)(i)(i) [inserted: ]
[inserted: that was not directed by the individual’s health care practitioner; or]
(68)(B)(ii)(ii) [inserted: ]
[inserted: that is not in accordance with the instructions for use on the labeling of such drug or substance.]
(69)(69) [inserted: ]
[inserted: The term “potential benefits to society” means, with respect to a drug or other substance, any medical, scientific, or other use of the drug or substance that may improve public health or quality of life.]

21 U.S.C. § 811 Authority and criteria for classification of substances

+1 −1Shown
More for 21 U.S.C. § 811
Read § 811Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 201(a) of the Controlled Substances Act (21 U.S.C. 811(a)) is amended by inserting before Rules of the Attorney General the following: In carrying out paragraph (1), the Attorney General shall (1) defer to the Secretary’s scientific and medical evaluation of a drug or other substance, and (2) add or transfer a drug or other substance to a schedule only if such schedule best corresponds to controls reasonably tailored to protect public health and safety (including the potential for abuse and dependence liability of the drug or substance) while preserving access for accepted medical uses, and recognizing the potential benefits to society, of the drug or substance..

§ 811(a)–(c)

Start of § 811 to (a)(1)(A) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(a)(1)(B)(B) (B)
makes with respect to such drug or other substance the findings prescribed by subsection (b) of section 812 of this title for the schedule in which such drug is to be placed; ormakes with respect to such drug or other substance the findings prescribed by subsection (b) of section 812 of this title for the schedule in which such drug is to be placed; or
(a)(2)(2) (2)
remove any drug or other substance from the schedules if he finds that the drug or other substance does not meet the requirements for inclusion in any schedule.remove any drug or other substance from the schedules if he finds that the drug or other substance does not meet the requirements for inclusion in any schedule.
(a)Rules of the Attorney General under this subsection shall be made on the record after opportunity for a hearing pursuant to the rulemaking procedures prescribed by subchapter II of chapter 5 of title 5. Proceedings for the issuance, amendment, or repeal of such rules may be initiated by the Attorney General (1) on his own motion, (2) at the request of the Secretary, or (3) on the petition of any interested party.[inserted: In carrying out paragraph (1), the Attorney General shall (1) defer to the Secretary’s scientific and medical evaluation of a drug or other substance, and (2) add or transfer a drug or other substance to a schedule only if such schedule best corresponds to controls reasonably tailored to protect public health and safety (including the potential for abuse and dependence liability of the drug or substance) while preserving access for accepted medical uses, and recognizing the potential benefits to society, of the drug or substance. ]Rules of the Attorney General under this subsection shall be made on the record after opportunity for a hearing pursuant to the rulemaking procedures prescribed by subchapter II of chapter 5 of title 5. Proceedings for the issuance, amendment, or repeal of such rules may be initiated by the Attorney General (1) on his own motion, (2) at the request of the Secretary, or (3) on the petition of any interested party.
(b)(b) Evaluation of drugs and other substances(b) Evaluation of drugs and other substances
The Attorney General shall, before initiating proceedings under subsection (a) to control a drug or other substance or to remove a drug or other substance entirely from the schedules, and after gathering the necessary data, request from the Secretary a scientific and medical evaluation, and his recommendations, as to whether such drug or other substance should be so controlled or removed as a controlled substance. In making such evaluation and recommendations, the Secretary shall consider the factors listed in paragraphs (2), (3), (6), (7), and (8) of subsection (c) and any scientific or medical considerations involved in paragraphs (1), (4), and (5) of such subsection. The recommendations of the Secretary shall include recommendations with respect to the appropriate schedule, if any, under which such drug or other substance should be listed. The evaluation and the recommendations of the Secretary shall be made in writing and submitted to the Attorney General within a reasonable time. The recommendations of the Secretary to the Attorney General shall be binding on the Attorney General as to such scientific and medical matters, and if the Secretary recommends that a drug or other substance not be controlled, the Attorney General shall not control the drug or other substance. If the Attorney General determines that these facts and all other relevant data constitute substantial evidence of potential for abuse such as to warrant control or substantial evidence that the drug or other substance should be removed entirely from the schedules, he shall initiate proceedings for control or removal, as the case may be, under subsection (a).The Attorney General shall, before initiating proceedings under subsection (a) to control a drug or other substance or to remove a drug or other substance entirely from the schedules, and after gathering the necessary data, request from the Secretary a scientific and medical evaluation, and his recommendations, as to whether such drug or other substance should be so controlled or removed as a controlled substance. In making such evaluation and recommendations, the Secretary shall consider the factors listed in paragraphs (2), (3), (6), (7), and (8) of subsection (c) and any scientific or medical considerations involved in paragraphs (1), (4), and (5) of such subsection. The recommendations of the Secretary shall include recommendations with respect to the appropriate schedule, if any, under which such drug or other substance should be listed. The evaluation and the recommendations of the Secretary shall be made in writing and submitted to the Attorney General within a reasonable time. The recommendations of the Secretary to the Attorney General shall be binding on the Attorney General as to such scientific and medical matters, and if the Secretary recommends that a drug or other substance not be controlled, the Attorney General shall not control the drug or other substance. If the Attorney General determines that these facts and all other relevant data constitute substantial evidence of potential for abuse such as to warrant control or substantial evidence that the drug or other substance should be removed entirely from the schedules, he shall initiate proceedings for control or removal, as the case may be, under subsection (a).
(c)(c) Factors determinative of control or removal from schedules(c) Factors determinative of control or removal from schedules
In making any finding under subsection (a) of this section or under subsection (b) of section 812 of this title, the Attorney General shall consider the following factors with respect to each drug or other substance proposed to be controlled or removed from the schedules:In making any finding under subsection (a) of this section or under subsection (b) of section 812 of this title, the Attorney General shall consider the following factors with respect to each drug or other substance proposed to be controlled or removed from the schedules:

Rest of § 811 unchanged

Step through the changes